4 Comments
User's avatar
Dominika Wilczok's avatar

A must have for entrepreneurs 🔥 In the face of those who said you can't use drugs to "check off" sleep for longevity

Expand full comment
Alex Zhavoronkov's avatar

Just don't mix DORAs with PDE5 inhibitors 😻

Expand full comment
Robots and Chips's avatar

Really comprehensive anlysis of the orexin landscape! I think the brief mention of Jazz Pharmaceuticals' paused orexin agonist trial highlights an important aspect of this development race - the safety challenges are significant when you're trying to activate rather than block such a powerful neurological system. Jazz's experience with visual and cardiac side effects contrasts sharply with Takeda's apparent success in managing the safety profile of oveporexton. It makes you wonder if Jazz's existing expertise in sleep disorders through their oxybate franchise gave them the confidence to pursue this difficult target, but the risks proved substantial. The irony is that Jazz already dominates sleep with antagonist-like effects from sodium oxybate, so an agonist would have been a perfect complement to their portfolio.

Expand full comment
Michael Florea's avatar

Very good read. Have you noticed any long-term side effects of taking the antagonists? Definitely a use case for jetlag but I wonder about using them as daily sleep aids.

Expand full comment